



Biotech Daily

Wednesday August 24, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: ATOMO UP 8.45%; PRESCIENT DOWN 17%**
- * **PROBIOTEC REVENUE UP 51% TO \$182m; PROFIT UP 170% TO \$14m**
- * **TRAJAN REVENUE UP 41% TO \$108m; PROFIT DOWN 9.4% TO 1.7m**
- * **CYNATA FUJIFILM \$7m REVENUE; LOSS DOWN 29% TO \$5.4m**
- * **HERAMED PLACEMENT RAISES \$4m**
- * **PRESCIENT SHARE PLAN FOR \$8m**
- * **TELIX: FRANCE TLX250-CDx BLADDER CANCER TRIAL DOSED**
- * **QUEST REDUCES TO 5.6% IN KAZIA**
- * **ALIUM ALPHA REDUCES TO 5.5% OF MICROBA**
- * **CREDIT SUISSE BELOW 5% IN HEXIMA - THEN TAKES 5.7%**

MARKET REPORT

The Australian stock market was up 0.52 percent on Wednesday August 24, 2022, with the ASX200 up 36.3 points to 6,998.1 points. Twelve of the Biotech Daily Top 40 stocks were up, 18 fell, eight traded unchanged and two were untraded. All three Big Caps fell.

Atomo was the best, up 0.6 cents or 8.45 percent to 7.7 cents, with 554,036 shares traded. Micro-X was up 7.4 percent; Telix climbed 6.25 percent; Antisense and Universal Biosensors were up more than five percent; Kazia improved 4.3 percent; Emvision and Mesoblast were up three percent or more; Pharmaxis rose 2.7 percent; Polynovo and Resonance were up more than one percent; with Paradigm up by 0.4 percent.

Prescient led the falls, down 3.5 cents or 16.7 percent to 17.5 cents, with 7.3 million shares traded. Cynata lost 10 percent; Genetic Signatures fell 8.5 percent; Actinogen and Impedimed were down more than six percent; Nanosonics was down 5.6 percent; Amplia, Next Science and Patrys fell four percent or more; Clinuvel, Imugene, Neuren, Pro Medicus and Volpara shed two percent or more; Immutep and Resmed were down more than one percent; with Cochlear, CSL, Medical Developments, Opthea and Starpharma down by less than one percent.

PROBIOTEC

Probiotec says revenue for the year to June 30, 2022 was up 51.3 percent to \$182,327,582 with net profit after tax up 170.4 percent to \$13,706,658.

Probiotec said revenue was from contract drug manufacturing and product development. The company said it would pay a fully-franked dividend of 3.5 cents a share for holders at the record date of September 8, to be paid on September 15, 2022, compared to the previous year's final dividend of 3.0 cents a share.

Probiotec said that "in light of the ongoing global covid-19 pandemic, the result for the year shows the defensive and resilient nature of the group's businesses".

The company said it acquired H&H Packaging on August 1 2021 for \$4 million and "despite difficult trading conditions, achieved growth in both revenue and earnings [and] continued to acquire and on-board new customers and contracts".

Probiotec said diluted earnings per share rose 167.2 percent to 17.10 cents, with cash and equivalents of \$22,203,568 at June 30, 2022 compared to a previous \$28,426,756. Probiotec was up seven cents or 3.2 percent to \$2.28.

TRAJAN GROUP

Trajan says revenue for the year to June 30, 2022 was up 40.5 percent to \$107,574,000 with net profit after tax down 9.4 percent to \$1,704,000.

Trajan said that in the year to June 30, 2022, it had acquired the two Sprockhövel, Germany-based Axel Semrau business for \$26.4 million, that Torrance, California-based blood micro-sampling company Neoteryx for \$6.96 million and 4,659,843 shares, the Raleigh, North Carolina-based Leap Pal Parts and Consumables LLC for \$10.8 million and the Louisville Kentucky Chromatography Research Supplies for \$62 million.

The company said revenues came from sales of its "products, devices and solutions that are used in the analysis of biological, food, and environmental samples."

Trajan managing-director Stephen Tomisich said that at the initial public offer in May 2021 the company said that most of the \$90 million raised would be used to accelerate its mergers and acquisitions program.

"With four acquisitions completed in the last 12 months, we executed as planned, achieving valuable outcomes in each instance," Mr Tomisich said.

"These successful additions to the Trajan portfolio plus the underlying organic growth that continues at double-digit pace means, this financial year, Trajan is on track to more than double revenues compared to our IPO starting point," Mr Tomisich said.

The company said diluted earnings per share fell 80 percent to one cent, net tangible asset backing per share fell 88 percent to six cents, and it had cash and cash equivalents of \$13,164,000 at June 30, 2022 compared to \$51,717,000 at June 30, 2021.

Trajan was unchanged at \$2.15.

CYNATA THERAPEUTICS

Cynata says revenue for the year to June 30, 2022 was \$7,002,497, with net loss after tax down 29.2 percent to \$5,445,172.

Cynata said the revenue primarily came from its partnership with Fujifilm, under which it received \$US5 million (\$A6.9 million) (BD: Sep 30, Oct 18, 2021).

The company said diluted loss per share fell 35.6 percent from 5.90 cents to 3.80 cents, with net tangible asset backing per share down 16.2 percent to 15 cents, and cash and cash equivalents of \$23,798,046, compared to \$26,716,670 for the year to June 30, 2021. Cynata fell four cents or 10 percent to 36 cents.

HERAMED

Heramed says it has raised \$4 million in a placement at 13 cents a share, a 13.3 percent discount to the company's closing price before its trading halt.

Heramed said the funds would be used as working capital, to build inventory, develop its technology platform, and increase staff in the US, Australia, New Zealand, and Israel.

The company said that for each three shares acquired, investors would receive one attaching option exercisable at 22 cents each by April 28, 2024.

Heramed said Pac Partners acted was the lead manager for the placement.

Heramed was unchanged at 15 cents with 2.8 million shares traded.

PRESCIENT THERAPEUTICS

Prescient says it hopes to raise \$8 million in a share purchase plan at 17.5 cents a share, a 14.6 percent discount to the 5-day volume weighted average price.

Prescient said the funds would be used for clinical development of PTX-100 and PTX-200, and progressing them into clinical studies, as well as for general working capital.

The company said the record date for the share plan was August 23, it would open on August 24, and close on September 28, 2022.

Prescient fell 3.5 cents or 16.7 percent to 17.5 cents with 7.3 million shares traded.

TELIX PHARMACEUTICALS

Telix says dosing has been completed dosing in a France, investigator-led, six-patient, phase I study of TLX250-CDx for non-muscle invasive bladder cancer.

In 2019, Telix said it had an up-to \$30 million licencing agreement with the Nantes, France-based Atonco for its molecularly targeted radiation intellectual property relating to the use of astatine-211 for non-muscle invasive bladder cancer (BD: Dec 16, 2019).

Today, in an announcement published on Twitter and emailed to shareholders but not published on the ASX, Telix said the open-label, proof-of-concept study would evaluate the safety, biodistribution and dosing properties of TLX250-CDx (zirconium-89-DFO-girentuximab) as a therapy for non-muscle invasive bladder cancer.

The company said that should the trial prove successful, the next stage would be to start therapeutic studies of Atonco's astatine-211 as a targeted radiotherapy agent.

The company said the trial was being conducted at the Saint Herblain-based Institut de Cancérologie de l'Ouest.

Telix chief medical officer Dr Colin Hayward congratulated Dr Caroline Rousseau and her team at Institut de Cancérologie de l'Ouest for recruiting the trial ahead of time.

"Subject to positive outcomes, we look forward to Atonco proceeding to therapeutic studies with astatine-211 and exploring targeted alpha therapy in bladder cancer, as part of Telix's and Atonco's drive to establish category leadership in urologic oncology," Dr Hayward said.

Telix was up 38 cents or 6.25 percent to \$6.46 with 1.6 million shares traded.

KAZIA THERAPEUTICS

Quest Asset Partners says it has reduced its substantial holding in Kazia from 9,366,195 shares (6.72%) to 8,346,656 shares (5.58%).

Quest said that between August 11 and 18, 2022, it sold 1,019,539 shares for \$255,460, or 25.1 cents a share.

Kazia was up one cent or 4.3 percent to 24.5 cents.

MICROBA LIFE SCIENCES

Alium Alpha Fund says it has reduced its substantial holding in Microba with from 19,874,882 shares (7.24%) to 14,985,993 (5.46%).

In a substantial shareholder notice signed by director Michael Considine, Alium said that between April 5 and September 18 it bought and sold 4,888,889 shares, but did not specify the price received, as required under the Corporations Act of 2001.

Microba fell one cent or 4.8 percent to 20 cents.

HEXIMA

Credit Suisse Holdings Australia says it has ceased to be a substantial holder in Hexima, and later in the day returned to substantial, with 5.72 percent.

After the market closed last Friday, Credit Suisse said it had become substantial in Hexima with 8,497,650 shares or 5.09 percent of the company (BD: Aug 22, 2022).

In June, Hexima fell 84.6 percent to four cents on news that its phase II clinical study of pezadeftide (HXP124) for onychomycosis was “inconclusive ... [and did] not support moving directly into a phase III program” (BD: Jun 24, 2022).

In July, Hexima fell a further 48.15 percent to 1.4 cents on news that following the failure of HXP124 to show efficacy for nail fungus it had begun the process of winding-up activities (BD: Jul 11, 2022).

Today, Credit Suisse said it sold 306,542 shares for \$3,832, or 1.2 cents a share.

Biotech Daily calculates that Credit Suisse retains 8,191,108 shares or 4.9 percent of Hexima.

Shortly before the market closed, Credit Suisse said it had returned to substantial with 9,551,108 shares or 5.72 percent.

Biotech Daily will no longer report Credit Suisse's adventures with Hexima.

Hexima fell 0.1 cents or 7.7 percent to 1.2 cents with 1.1 million shares traded.